The firm said it feels comfortable about its runway through 2026. The post Atai cash purse down nearly half despite...
A debate about accessibility, safety, and cost has emerged around ketamine telehealth as the pandemic waiver that paused mandatory in-person evaluation...
There has been a lot of negative news over the past year. A war in Europe. Inflation running at decade highs. Economic indicators suggesting an incoming...
The article Death, Hope, and The Psychedelic Experience was originally published on Microdose. I am a person of hope and potential. As a two-time cancer...
Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry...
The article New Study: Challenging Psychedelic Trips Lead to Positive Mental Health was originally published on Microdose. A new study suggests that challenging...
The medical model proposal, which would set up a framework for psilocybin-assisted therapy in New York ahead of FDA approval, is viewed by some policy...
MindMed says it has enough cash to get to 2025. The post MindMed Has Big Goals For 2023 appeared first on Green Market Report.
What does the future of psychedelic medicine look like in the UK? What treatments might be available? How could they be accessed? Nowadays our news feeds...
The article Are LSD and r-MDMA the Future of Psychedelics? MindMed Says Yes was originally published on Microdose. On March 8th, MindMed (Nasdaq: MNMD,...
Satisfied clients, innovation, award-winning work, and experienced people drive double-digit revenue growth for the 21st consecutive year.
The pathogenic fungus Aspergillus fumigatus escapes elimination from surface cells of the human lung by binding to a human protein. In doing so, it is...
The article A Deeper Look at atai Life Sciences’ Corporate Update was originally published on Microdose. atai Life Science has released its most recent corporate...
A clinical trial launched by Sunstone Therapies demonstrated the effectiveness of group therapy as part of psilocybin-assisted therapy for depression. The...
There has been no shortage of first-of-their-kind psychedelic clinical trials over the past few years. There have historically been very few studies testing...
A gene therapy startup backed by two key biopharmas and two premier biotech VC firms has ceased operations. California biotech Coda Biotherapeutics shut...